GlobeImmune leads with $34.3 million second round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
GlobeImmune
|
$34.3 million
|
Lilly Ventures |
GlobeImmune is developing immunotherapy products called Tarmogens(TM) for the treatment of cancer and chronic infectious diseases. |
|
Kereos
|
$19.5 million
|
Prolog Ventures |
Kereos is advancing its lead product candidates KI-0001, a targeted imaging agent to detect various solid tumors, and KI-1001, a targeted chemotherapeutic to selectively destroy tumors, through Phase I/II clinical trials. |
|
Teranode Corporation
|
$9.5 million
|
Cargill Ventures and Trident Capital |
Teranode develops software for the life sciences industry. |
|
Caldera Pharmaceuticals
|
$7 million
|
Individuals |
Caldera is developing a system that allows for faster testing of chemical samples against an array of proteins. |
|
Chiasma
|
$6.2 million
|
F-2 Ventures and the Ofer Hi-Tech Group |
Chiasma has been developing platform technology for the oral delivery of macromolecule drugs. |
|
Athenagen
|
$5.69 million
|
Sanderling Ventures |
Athenagen is developing small-molecule drugs designed to either inhibit or enhance angiogenesis, based on the discovery of a new endothelial cell angiogenesis pathway. |
|
Dimerix
|
Undisclosed
|
Foundation Capital |
Dimerix is striving to develop more effective drugs with fewer side-effects, by applying its technologies to novel G-Protein Coupled Receptor (GPCR) cluster targets. |